Copyright
©The Author(s) 2025.
World J Gastroenterol. Jul 7, 2025; 31(25): 105518
Published online Jul 7, 2025. doi: 10.3748/wjg.v31.i25.105518
Published online Jul 7, 2025. doi: 10.3748/wjg.v31.i25.105518
Table 1 Demographic, clinical, histological and biochemical characteristics of the enrolled patients
Characteristic | Entire cohort (n = 120) | No MASH (n = 39) | MASH (n = 81) | P value |
Sex (male) | 68 (56.7) | 24 (61.5) | 44 (54.3) | NS |
Age (years) | 49 ± 11 | 50 ± 10 | 49 ± 11 | NS |
BMI (kg/m2) | 33.2 ± 7.1 | 31.7 ± 6.9 | 34.0 ± 7.1 | NS |
Obesity | 72 (60.0) | 19 (48.7) | 53 (65.4) | 0.08 |
Diabetes | 35 (29.1) | 7 (17.9) | 28 (34.5) | 0.06 |
Hypertension | 54 (45.0) | 14 (35.9) | 40 (49.4) | NS |
Biochemical profile | ||||
Platelet count (× 106/mL) | 230.9 ± 68.2 | 230.6 ± 59.0 | 231.0 ± 72.6 | NS |
AST (IU/L) | 43.7 ± 38.9 | 32.3 ± 14.3 | 49.3 ± 45.3 | 0.02 |
ALT (IU/L) | 59.2 ± 50.2 | 42.4 ± 23.9 | 67.2 ± 57.2 | 0.01 |
GGT (IU/L) | 65.7 ± 56.2 | 68.6 ± 73.2 | 64.3 ± 47.3 | NS |
ALP (IU/L) | 74.7 ± 37.1 | 85.7 ± 52.6 | 69.6 ± 25.9 | 0.03 |
Albumin (g/L) | 40.9 ± 3.5 | 41.6 ± 3.2 | 40.5 ± 3.5 | NS |
Triglycerides (mg/dL) | 157.9 ± 90.6 | 137.5 ± 53.7 | 168.0 ± 103.1 | NS |
Total cholesterol (mg/dL) | 196.3 ± 44.2 | 195.9 ± 42.0 | 196.5 ± 45.5 | NS |
HDL (mg/dL) | 44.7 ± 14.3 | 50.1 ± 22.5 | 42.7 ± 8.8 | 0.04 |
FIB4 | 1.54 ± 2.67 | 1.20 ± 0.61 | 1.71 ± 3.22 | NS |
NFS | -1.24 ± 1.71 | -1.54 ± 1.48 | -1.10 ± 1.80 | NS |
Agile3 + | 0.14 (0.06-0.53) | 0.11 (0.05-0.33) | 0.23 (0.06-0.60) | 0.02 |
Histological findings | ||||
Steatosis grade | < 0.01 | |||
1 | 47 (39.2) | 39 (100) | 8 (9.9) | |
2 | 49 (40.8) | 0 (0) | 49 (60.5) | |
3 | 24 (20.0) | 0 (0) | 24 (29.6) | |
Lobular inflammation grade | < 0.01 | |||
0 | 4 (3.3) | 4 (10.2) | 0 (0) | |
1 | 90 (75.0) | 35 (89.8) | 55 (67.9) | |
2 | 24 (20.0) | 0 (0) | 24 (29.6) | |
3 | 2 (1.7) | 0 (0) | 2 (2.5) | |
Hepatocyte ballooning grade | < 0.01 | |||
0 | 13 (10.8) | 13 (33.3) | 0 (0) | |
1 | 94 (78.4) | 26 (66.6) | 68 (84.2) | |
2 | 13 (10.8) | 0 (0) | 13 (15.8) | |
Fibrosis stage | 0.01 | |||
0 | 3 (2.5) | 3 (7.7) | 0 (0) | |
1 | 43 (35.8) | 19 (48.8) | 24 (29.6) | |
2 | 40 (33.3) | 12 (30.7) | 28 (34.6) | |
3 | 30 (25.0) | 4 (10.2) | 26 (32.1) | |
4 | 4 (3.4) | 1 (2.6) | 3 (3.7) | |
Elastographic measurements | ||||
LS by TE (kPa) | 7.9 ± 5.0 | 6.2 ± 3.2 | 8.7 ± 5.3 | 0.01 |
2D-SWE (kPa) | 7.34 ± 3.16 | 6.61 ± 3.02 | 7.70 ± 3.19 | 0.07 |
CAP (dB/m) | 302.9 ± 67.2 | 250.5 ± 74.5 | 328.2 ± 45.9 | < 0.01 |
Att.PLUS (dB/cm/mHz) | 0.52 ± 0.11 | 0.55 ± 0.12 | 0.51 ± 0.10 | 0.06 |
SSp.PLUS (m/s) | 1530 (1505-1550) | 1545 (1525-1570) | 1525 (1500-1545) | < 0.01 |
Vi.PLUS (Pa.s) | 2.24 ± 0.51 | 2.04 ± 0.54 | 2.34 ± 0.48 | 0.03 |
Table 2 Performance of ultrasound non-invasive diagnostic tests and VAS-MASH-US score for predicting moderate-to-severe steatosis (S ≥ 2), presence of both lobular inflammation and ballooning (inflammation ≥ 1 and ballooning ≥ 1), MASH (NAS score ≥ 4 and least 1 point at steatosis, lobular inflammation, and ballooning) and Fibrosis
Variable | Cutoff value | AUC (95%CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | P value |
Steatosis ≥ 2 | |||||||
CAP (dB/m) | 275 | 0.83 (0.75-0.91) | 94.5 | 66.0 | 81.2 | 88.6 | Reference |
CAP (dB/m) | 3011 | 78.0 | 74.5 | 82.6 | 68.6 | ||
Att.PLUS (dB/cm/mHz) | 0.44 | 0.60 (0.50-0.70) | 89.4 | 31.5 | 45.6 | 82.1 | < 0.01 |
SSp.PLUS (m/s) | 1535 | 0.71 (0.61-0.81) | 70.2 | 65.7 | 56.9 | 77.4 | 0.02 |
Inflammation ≥ 1 and ballooning ≥ 1 | |||||||
Vi.PLUS (Pa.s) | 2.3 | 0.72 (0.59-0.86) | 52.8 | 92.8 | 98.2 | 20.6 | Reference |
MASH | |||||||
Vi.PLUS (Pa.s) | 2.1 | 0.68 (0.58-0.79) | 69.1 | 64.1 | 80.0 | 50.0 | Reference |
VAS-MASH-US score | 0.60 | 0.75 (0.65-0.84) | 79.0 | 66.7 | 83.1 | 60.4 | 0.14 |
0.48 | 90.0 | 43.6 | 76.6 | 65.4 | |||
0.84 | 30.9 | 90.0 | 86.2 | 38.4 | |||
Fibrosis ≥ 2 | |||||||
TE (kPa) | 6.4 | 0.75 (0.65-0.83) | 72.9 | 71.7 | 80.6 | 62.3 | Reference |
2D-SWE (kPa) | 6.4 | 0.69 (0.60-0.79) | 59.5 | 73.9 | 78.6 | 53.1 | 0.25 |
FIB-4 | 1.07 | 0.65 (0.55-0.75) | 62.2 | 58.7 | 70.8 | 49.1 | 0.10 |
NFS | -0.97 | 0.69 (0.59-0.79) | 55.4 | 78.3 | 80.4 | 52.2 | 0.40 |
Vi.PLUS (Pa.s) | 2.3 | 0.64 (0.53-0.74) | 59.5 | 71.7 | 77.2 | 52.4 | 0.04 |
Fibrosis ≥ 3 | |||||||
TE (kPa) | 81 | 91.2 | 83.7 | 68.9 | 96.0 | Reference | |
8.4 | 0.93 (0.87-0.99) | 85.3 | 91.9 | 80.5 | 94.0 | ||
121 | 35.3 | 97.7 | 84.6 | 78.5 | |||
2D-SWE (kPa) | 7.2 | 0.90 (0.85-0.95) | 88.2 | 81.4 | 61.7 | 93.1 | 0.43 |
FIB-4 | 1.26 | 0.80 (0.71-0.89) | 70.6 | 74.4 | 52.2 | 86.5 | 0.01 |
NFS | -1.12 | 0.83 (0.75-0.90) | 88.2 | 73.2 | 56.6 | 94.0 | 0.03 |
Agile3 + | 0.42 | 0.93 (0.88-0.98) | 85.3 | 89.5 | 76.3 | 93.9 | 0.99 |
Vi.PLUS (Pa.s) | 2.1 | 0.81 (0.74-0.89) | 100 | 58.1 | 48.6 | 100 | < 0.01 |
Table 3 Univariate and multivariate analysis evaluating variables associated with metabolic dysfunction-associated steatohepatitis
Variable | Univariate analysis | Multivariate analysis | ||
OR (95%CI) | P value | OR (95%CI) | P value | |
Sex (male) | 0.74 (0.34-1.62) | 0.45 | ||
Age | 0.98 (0.95-1.02) | 0.48 | ||
Att.PLUS | 0.03 (0.01-1.06) | 0.06 | ||
SSp.PLUS | 0.98 (0.97-0.99) | < 0.01 | 0.98 (0.97-0.99) | < 0.01 |
CAP | 1.02 (1.01-1.03) | < 0.01 | ||
Vi.PLUS | 3.59 (1.47-8.78) | < 0.01 | 3.12 (1.20-8.16) | 0.02 |
BMI (kg/m2) | 1.05 (0.99-1.11) | 0.11 | ||
Triglycerides | 1.00 (0.99-1.01) | 0.11 | ||
Total cholesterol | 1.00 (0.99-1.01) | 0.94 | ||
Diabetes | 2.42 (0.95-6.17) | 0.06 | ||
Hypertension | 1.74 (0.79-3.82) | 0.16 | ||
ALT | 1.02 (1.01-1.03) | 0.01 | 1.03 (1.01-1.06) | 0.05 |
AST | 1.03 (1.01-1.06) | 0.02 |
- Citation: Liguori A, Ainora ME, Di Gialleonardo L, Viceconti N, Petrucci L, Esposto G, Giustiniani MC, Mignini I, Borriello R, Galasso L, Paratore M, Garcovich M, Riccardi L, Pompili M, Grieco A, Gasbarrini A, Miele L, Zocco MA. Multiparametric ultrasound for non-invasive assessment of liver steatosis, fibrosis, and inflammation in metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2025; 31(25): 105518
- URL: https://www.wjgnet.com/1007-9327/full/v31/i25/105518.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i25.105518